ERNEXA THERAPEUTICS INC (ERNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.31-4.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ERNA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | |
|---|---|---|---|
| Revenues | |||
| Revenues | — | — | 0.6 |
| Total Revenues | — | — | 0.6 |
| Cost of Revenues | — | — | 0.1 |
| Gross Profit | — | — | 0.5 |
| Operating Expenses & Income | |||
| Operating Income | (13.8) | (9.3) | (15.7) |
| Earnings from Continuing Operations | |||
| Interest Expense | — | (0.1) | 6.5 |
| Other Non-Operating Income / Expenses | 1.4 | (4.8) | (28.8) |
| EBT, Incl. Unusual Items | (12.4) | (14.1) | (44.5) |
| Income Tax Expense | — | (0.0) | 0.0 |
| Net Income | |||
| Net Income | (12.3) | (14.1) | (44.5) |
| Per Share | |||
| Basic EPS | (10.36) | (2.24) | (3.26) |
| Diluted EPS | (10.36) | (2.24) | (3.26) |
| Basic Weighted Avg Shares | 1.2 | 6.3 | 13.6 |
| Diluted Weighted Avg Shares | 1.2 | 6.3 | 13.6 |
| Supplemental | |||
| EBITDA | — | (9.2) | (15.6) |
| EBIT | (13.8) | (9.3) | (15.7) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.